Material Event Form 8 K

Item 8.01. Other Events.

​

As previously disclosed, on March 26, 2024, Ovid Therapeutics, Inc. ("Ovid") filed a petition (the "Petition") with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (the "PTAB")seeking Inter Partes Review ("IPR") of one of the patents of Marinus Pharmaceuticals, Inc, (the "Company") for the use of ganaxolone in treating status epilepticus (U.S. Patent No. 11,110,100). The Company filed a preliminary response to Ovid's petition on June 26, 2024.

​

On September 20, 2024, the PTAB issued a decision denying institution of the IPR, stating that Ovid has not established a reasonable likelihood that it would prevail in showing the unpatentability of at least one claim challenged in the Petition. The decision is publicly available on the U.S. Patent Office's website (uspto.gov). Ovid could choose to file for rehearing or seek director review at the PTAB within 30 days from the September 20, 2024 PTAB decision date. Ovid cannot appeal the denial of institution to the U.S. Court of Appeals for the Federal Circuit.

​

​

​

​

​

​

​

​

​

​

​